As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers. Spherix Global Insights ...
Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs. The Danish drugmaker ...
Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million ‌on U.S. advertising for its GLP-1 drugs Wegovy and ‌Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results